Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Chronic Kidney Disease (CKD) is associated with bone changes and very high fracture rates. A component of bone is marrow. Bone marrow fat is increased in patients with CKD compared to those in the normal population of the same age. It is not clear if there will be changes in the marrow fact content in those with CKD on Pioglitazone. In people with normal kidney function, thiazolidinedione group of drugs have had variable effects on bone marrow fat content, as measured by MRS. This is important as changes in marrow fat are likely related to changes in the bone in patients with chronic kidney disease.
Condition or disease
Polycystic Kidney Diseases
Other: No intervention
If patients consent to participate in the ancillary study of marrow fat changes with pioglitazone, those that are randomized to placebo or 15 mg pioglitazone for 12 months (per the criteria in the main study) will also undergo magnetic resonance spectroscopy (MRS) of the lumbar spine at L1, L2 and L3. MR spectroscopy of the lumbar spine (if they choose as this is ancillary study) will be performed 3 times over the course of the study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 55 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
PKD subjects that consent to the FDA study, number 1308084213, will be approached for consenting for this bone marrow fat study.
Subject must be enrolled in NCT#02697617
Included subjects will be those who consent to the study of Pioglitazone in ADPKD (Protocol number 1308084213). Therefore inclusion and exclusion criteria are the same as for that study. Subjects will NOT be offered participation in the bone marrow fat study till after they consent for the FDA approved study. Subjects who withdraw from the FDA approved study will be withdrawn from this protocol.
Inclusion/Exclusion Criteria for NCT#02697617
Male or female ADPKD patients aged 18-55
eGFR at or above ≥ 50 ml/min/1.73 m2 by 4 parameter MDRD or CKD-Epiformulas
normal liver enzymes (ALT/AST)
fasting blood glucose between 70 and120
for female patients, a willingness to use double contraception to avoid pregnancy while in study
able to give informed consent
In the opinion of the investigator, high likelihood of progressive kidney disease
diabetes, defined as any of the following: fasting blood sugar > 130 times two, HgbA1C > 7, on any blood sugar lowering medication, or past diagnosis of diabetes not occurring during pregnancy
uncontrolled hypertension, defined as systolic > 150, diastolic > 90 despite an attempt by physician to titrate medications
history of impaired systolic function (ejection fraction < 50%) by previous ECHO or known ischemic cardiovascular disease
findings suggestive of a kidney disease other than ADPKD
systemic illness requiring immunosuppressive or anti-inflammatory agents
congenital absence of a kidney or history of a total nephrectomy
history of cyst reduction or partial nephrectomy
history of renal cyst aspiration within the previous year
History of bladder cancer, or gross hematuria
inability to undergo MRI due to implantable devices or foreign objects that preclude MRI
active renal transplant
allergy or sensitivity to any of the components of the test materials
currently pregnant or plans to become pregnant during the study